Kalvista sets sight on DMO with kallikrein inhibitors
This article was originally published in Scrip
Executive Summary
A newly launched UK biotech company, KalVista Pharmaceuticals, will focus on treating diabetic macular oedema (DMO) using small molecule plasma kallikrein inhibitors acquired from Vantia Therapeutics.